Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 196 participants.
Also called NCT06660524
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 196 participants
- Registry
-
NCT06660524
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT06660524. Randomized; no masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
- Condition
- Degenerative Heart Valve Disease
- Condition
- Heart Valve Calcification
- Condition
- Calcium-Phosphorus Metabolism Disorders
- Intervention (Drug)
- Sevelamer
- Intervention (Drug)
- Calcium carbonate
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct06660524- Content hash
4324989369e9621689f0ff7dd40788da7d858f01084671b410ad77a7296fe7f3